Intarcia Therapeutics Obtains $200,000,000 New Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=2c4017a8-3478-4333-a8e9-271ec212ff3e
Date
4/1/2014
Company Name
Intarcia Therapeutics
Mailing Address
155 Seaport Boulevard 11th Floor Boston, MA 02210 USA
Company Description
Intarcia Therapeutics Inc, a privately held pharmaceutical company, is developing therapies for the treatment of cancer, immunological, and infectious diseases.
Website
http://www.intarcia.com
Transaction Type
Venture Equity
Transaction Amount
$200,000,000
Transaction Round
Undisclosed
Proceeds Purposes
In this latest transaction, Intarcia further retains control of its lead product candidate ITCA 650 – its novel once-yearly GLP-1 for type two diabetes, currently being investigated in a global phase 3 clinical trial program called FREEDOM.
M&A Terms
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor